PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 270 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,373,497 | +0.5% | 77,363 | +31.2% | 0.01% | 0.0% |
| Q2 2023 | $2,362,687 | +59.3% | 58,964 | +62.3% | 0.01% | +40.0% |
| Q1 2023 | $1,482,913 | -60.3% | 36,337 | -62.4% | 0.01% | -61.5% |
| Q4 2022 | $3,733,857 | +346.6% | 96,707 | +574.8% | 0.01% | +225.0% |
| Q2 2022 | $836,000 | +164.6% | 14,331 | +173.3% | 0.00% | +300.0% |
| Q4 2021 | $316,000 | -93.0% | 5,244 | -93.1% | 0.00% | -95.0% |
| Q4 2020 | $4,527,000 | -62.1% | 75,647 | -61.9% | 0.02% | -57.4% |
| Q3 2020 | $11,942,000 | +8.2% | 198,637 | -5.5% | 0.05% | -16.1% |
| Q2 2020 | $11,033,000 | +37.2% | 210,279 | -12.3% | 0.06% | +7.7% |
| Q1 2020 | $8,043,000 | +113.3% | 239,883 | +188.3% | 0.05% | +333.3% |
| Q4 2019 | $3,770,000 | +236.3% | 83,220 | +182.6% | 0.01% | +200.0% |
| Q3 2019 | $1,121,000 | +43.2% | 29,446 | +63.6% | 0.00% | +33.3% |
| Q2 2019 | $783,000 | +27.9% | 18,000 | +26.6% | 0.00% | 0.0% |
| Q4 2018 | $612,000 | -72.8% | 14,217 | -69.0% | 0.00% | -62.5% |
| Q3 2018 | $2,251,000 | +449.0% | 45,817 | +258.0% | 0.01% | +300.0% |
| Q2 2018 | $410,000 | – | 12,799 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tamarack Advisers, LP | 360,000 | $21,845,000 | 6.19% |
| Gagnon Advisors, LLC | 213,217 | $12,938,000 | 4.92% |
| GAGNON SECURITIES LLC | 499,333 | $30,300,000 | 4.30% |
| Spyglass Capital Management LLC | 2,117,673 | $128,500,000 | 2.86% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 646,530 | $39,231,000 | 2.30% |
| Paulson & Co. | 1,273,161 | $77,255,000 | 1.85% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 212,112 | $12,871,000 | 1.44% |
| Tygh Capital Management, Inc. | 152,332 | $9,244,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,147,000 | $69,600,000 | 1.24% |
| Rock Springs Capital Management LP | 1,025,000 | $62,197,000 | 1.23% |